PL2493895T3 - Zawierające azot (N) heteroarylowe pochodne jako inhibitory kinazy JAK3 - Google Patents
Zawierające azot (N) heteroarylowe pochodne jako inhibitory kinazy JAK3Info
- Publication number
- PL2493895T3 PL2493895T3 PL10771146T PL10771146T PL2493895T3 PL 2493895 T3 PL2493895 T3 PL 2493895T3 PL 10771146 T PL10771146 T PL 10771146T PL 10771146 T PL10771146 T PL 10771146T PL 2493895 T3 PL2493895 T3 PL 2493895T3
- Authority
- PL
- Poland
- Prior art keywords
- kinase inhibitors
- containing heteroaryl
- jak3 kinase
- heteroaryl derivatives
- derivatives
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382233 | 2009-10-29 | ||
| US29105109P | 2009-12-30 | 2009-12-30 | |
| US32992710P | 2010-04-30 | 2010-04-30 | |
| PCT/EP2010/066476 WO2011051452A1 (en) | 2009-10-29 | 2010-10-29 | N-containing heteroaryl derivatives as jak3 kinase inhibitors |
| EP10771146.7A EP2493895B1 (en) | 2009-10-29 | 2010-10-29 | N-containing heteroaryl derivatives as jak3 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2493895T3 true PL2493895T3 (pl) | 2017-10-31 |
Family
ID=41571618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10771146T PL2493895T3 (pl) | 2009-10-29 | 2010-10-29 | Zawierające azot (N) heteroarylowe pochodne jako inhibitory kinazy JAK3 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8501735B2 (pl) |
| EP (1) | EP2493895B1 (pl) |
| JP (1) | JP5759471B2 (pl) |
| KR (1) | KR101675614B1 (pl) |
| CN (1) | CN102712658B (pl) |
| AR (1) | AR078833A1 (pl) |
| AU (1) | AU2010311378B2 (pl) |
| BR (1) | BR112012010186B8 (pl) |
| CA (1) | CA2778680C (pl) |
| DK (1) | DK2493895T3 (pl) |
| ES (1) | ES2629006T3 (pl) |
| IL (1) | IL219385A0 (pl) |
| MX (1) | MX2012005100A (pl) |
| PE (1) | PE20121352A1 (pl) |
| PL (1) | PL2493895T3 (pl) |
| PT (1) | PT2493895T (pl) |
| RU (1) | RU2553681C2 (pl) |
| SI (1) | SI2493895T1 (pl) |
| TW (1) | TWI478714B (pl) |
| UA (1) | UA109775C2 (pl) |
| WO (1) | WO2011051452A1 (pl) |
| ZA (1) | ZA201203090B (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| EP2397482A1 (en) * | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| WO2012003576A1 (en) * | 2010-07-06 | 2012-01-12 | Université de Montréal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| CA2825098C (en) | 2011-01-27 | 2020-03-10 | Universite De Montreal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| WO2013025628A1 (en) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| CN104053661B (zh) | 2011-11-23 | 2018-06-19 | 癌症研究技术有限公司 | 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂 |
| WO2013117649A1 (en) * | 2012-02-10 | 2013-08-15 | Galapagos Nv | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
| UY34615A (es) * | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. |
| TW201513861A (zh) * | 2013-01-17 | 2015-04-16 | Galapagos Nv | 用於治療退化性及發炎疾病之新穎化合物 |
| US9650376B2 (en) | 2013-03-15 | 2017-05-16 | Knopp Biosciences Llc | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators |
| TWI663159B (zh) | 2013-12-10 | 2019-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑 |
| KR102409739B1 (ko) | 2014-03-20 | 2022-06-17 | 카펠라 테라퓨틱스, 인크. | 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체 |
| ES2960991T3 (es) | 2014-09-12 | 2024-03-07 | Biohaven Therapeutics Ltd | Benzoimidazol-1,2-ilamidas como activadores del canal Kv7 |
| TWI780438B (zh) | 2014-12-18 | 2022-10-11 | 美商健臻公司 | 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物 |
| EP3053927A1 (en) | 2015-02-05 | 2016-08-10 | Vectura Limited | Novel polymorphs |
| US10155757B2 (en) | 2015-03-10 | 2018-12-18 | Vectura Limited | Crystalline form of a JAK3 kinase inhibitor |
| RU2750151C2 (ru) | 2015-11-20 | 2021-06-22 | Форма Терапьютикс, Инк. | Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1 |
| ES2946551T3 (es) | 2017-10-17 | 2023-07-20 | Palau Pharma S L U | Síntesis de compuestos de 4-aminopirimidina |
| TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| CA3177830A1 (en) | 2020-05-13 | 2021-11-18 | Maria BECONI | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN112724133B (zh) * | 2021-01-12 | 2022-03-25 | 湖南复瑞生物医药技术有限责任公司 | 6-溴吡唑并[1,5-a]吡啶的制备方法 |
| WO2023248010A2 (en) | 2022-06-23 | 2023-12-28 | Synovo Gmbh | Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases |
| EP4626403A2 (en) * | 2022-12-02 | 2025-10-08 | Kinaset Therapeutics, Inc. | Formulation of a pan-jak inhibitor |
| WO2026030543A1 (en) | 2024-07-31 | 2026-02-05 | Kinaset Therapeutics, Inc. | Treatment of copd patient populations |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| AU2003278088A1 (en) | 2002-10-28 | 2004-05-25 | Bayer Healthcare Ag | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
| EP1505064A1 (en) | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
| TW200618800A (en) * | 2004-08-03 | 2006-06-16 | Uriach Y Compania S A J | Heterocyclic compounds |
| AU2005278292B2 (en) * | 2004-08-31 | 2011-09-08 | Msd K.K. | Novel substituted imidazole derivatives |
| WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| KR20080013886A (ko) | 2005-04-05 | 2008-02-13 | 파마코페이아, 인코포레이티드 | 면역억제용 퓨린 및 이미다조피리딘 유도체 |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| WO2006110763A1 (en) | 2005-04-08 | 2006-10-19 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives and their use for the treatment of cancer |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| EP2532667A1 (en) * | 2005-09-30 | 2012-12-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| AR063141A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| TW200831104A (en) * | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| NZ576278A (en) | 2006-10-19 | 2011-12-22 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| CA2669686A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia, Llc | 7-substituted purine derivatives for immunosuppression |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| WO2008119792A1 (en) * | 2007-04-02 | 2008-10-09 | Palau Pharma, S. A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| WO2008143674A1 (en) | 2007-05-23 | 2008-11-27 | Pharmacopeia, Inc. | Purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| WO2009048474A1 (en) | 2007-10-12 | 2009-04-16 | Pharmacopeia, Inc. | 2,7,9-substituted purinone derivatives for immunosuppression |
| PE20091035A1 (es) | 2007-11-30 | 2009-07-16 | Palau Pharma Sa | Derivados de 2-aminopirimidina |
| WO2009077608A1 (en) | 2007-12-19 | 2009-06-25 | Palau Pharma, S. A. | 2 -aminopyrimidine derivatives as histamine h4 antagonists |
| RU2489430C2 (ru) | 2007-12-21 | 2013-08-10 | Палау Фарма, С.А. | Производные 4-аминопиримидина |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| EP2516420B8 (en) | 2009-12-23 | 2018-10-17 | Medicis Pharmaceutical Corporation | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |
| JP2011136925A (ja) * | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
-
2010
- 2010-10-29 PL PL10771146T patent/PL2493895T3/pl unknown
- 2010-10-29 CA CA2778680A patent/CA2778680C/en active Active
- 2010-10-29 ES ES10771146.7T patent/ES2629006T3/es active Active
- 2010-10-29 PE PE2012000600A patent/PE20121352A1/es not_active Application Discontinuation
- 2010-10-29 BR BR112012010186A patent/BR112012010186B8/pt active IP Right Grant
- 2010-10-29 CN CN201080059973.2A patent/CN102712658B/zh active Active
- 2010-10-29 MX MX2012005100A patent/MX2012005100A/es active IP Right Grant
- 2010-10-29 JP JP2012535851A patent/JP5759471B2/ja active Active
- 2010-10-29 WO PCT/EP2010/066476 patent/WO2011051452A1/en not_active Ceased
- 2010-10-29 US US13/504,157 patent/US8501735B2/en active Active
- 2010-10-29 EP EP10771146.7A patent/EP2493895B1/en active Active
- 2010-10-29 UA UAA201206551A patent/UA109775C2/ru unknown
- 2010-10-29 DK DK10771146.7T patent/DK2493895T3/en active
- 2010-10-29 RU RU2012122020/04A patent/RU2553681C2/ru active
- 2010-10-29 AU AU2010311378A patent/AU2010311378B2/en active Active
- 2010-10-29 TW TW099137263A patent/TWI478714B/zh active
- 2010-10-29 PT PT107711467T patent/PT2493895T/pt unknown
- 2010-10-29 AR ARP100103999A patent/AR078833A1/es active IP Right Grant
- 2010-10-29 KR KR1020127013343A patent/KR101675614B1/ko active Active
- 2010-10-29 SI SI201031506T patent/SI2493895T1/sl unknown
-
2012
- 2012-04-24 IL IL219385A patent/IL219385A0/en active IP Right Grant
- 2012-04-26 ZA ZA2012/03090A patent/ZA201203090B/en unknown
-
2013
- 2013-06-28 US US13/930,392 patent/US8946257B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201203090B (en) | N-containing heteroaryl derivatives as jak3 kinase inhibitors | |
| IL257083A (en) | History of phosphorus as kinase inhibitors | |
| GEP20135849B (en) | Picolinamide derivatives as kinase inhibitors | |
| IL210124A0 (en) | Pyrimidine derivatives as kinase inhibitors | |
| IL210990A0 (en) | Piperidine derivatives as jak3 inhibitors | |
| IL218271A0 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| IL213906A0 (en) | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase | |
| ZA201008808B (en) | Novel phenylpyrazinones as kinase inhibitors | |
| IL210292A0 (en) | Heteroaryl derivatives as dgat1 inhibitors | |
| IL211693A0 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| IL206394A0 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| IL212842A0 (en) | Azaindole derivatives as kinase inhibitors | |
| IL218114A0 (en) | 5-6-bicyclic heteroaryl-cotaining urea compounds as kinase inhibitors | |
| IL210573A0 (en) | Compounds as kinase inhibitors | |
| PL2231642T3 (pl) | Pirymidyny jako inhibitory kinazy | |
| ZA201008878B (en) | Naphthyridiniones as aurora kinase inhibitors | |
| IL220205A0 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| EP2611806A4 (en) | HETEROCYCLIC COMPOUNDS ENRICHED IN DEUTERIUM AS INHIBITORS OF KINASES |